The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), BP p.l.c. (BP) ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Brian Thompson, the CEO of UnitedHealth's insurance unit, was fatally shot in midtown Manhattan last week in what police ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...